Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis
Status:
Completed
Trial end date:
2002-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effectiveness and safety of the experimental compound OP2000
(deligoparin) in patients with active ulcerative colitis. Patients eligible for this study
will have received (and will continue to receive) stable doses of aminosalicylates (oral,
enema and/or suppository), if tolerated. OP2000 is an ultra low molecular weight heparin with
anticoagulant (blood thinning) and anti-inflammatory actions that may be of benefit for the
treatment of ulcerative colitis.